Arrowhead Pharmaceuticals: More Questions Than Answers After Data Obesity Update [Seeking Alpha]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Seeking Alpha
INHBE-targeted monotherapy is unlikely to drive meaningful weight loss. Combination data with tirzepatide showed promising weight loss, but tiny sample sizes and missing datasets raise concerns about the true efficacy. I remain bullish on ARWR for its broader pipeline, not for ARO-INHBE or ARO-ALK7, which I treat as upside optionality until stronger data emerge. Looking for a helping hand in the market? Members of Growth Stock Forum get exclusive ideas and guidance to navigate any climate. Learn More » Henrik Sorensen/DigitalVision via Getty Images Shares of Arrowhead Pharmaceuticals, Inc. ( ARWR ) rose today as the markets reacted to what I consider very selective and incomplete first data disclosures from the phase 1 trials of ARO-INHBE and ARO-ALK7, the More on my IG service I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.MarketBeat
- Is Arrowhead Pharmaceuticals Stock a Buy or Sell After the CEO Sold Shares Worth $5.4 Million? [Yahoo! Finance]Yahoo! Finance
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After REDEMPLO Approvals And New Obesity Trial Data [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded WarrantsBusiness Wire
ARWR
Earnings
- 11/25/25 - Miss
ARWR
Sec Filings
- 1/12/26 - Form 8-K
- 1/9/26 - Form 8-K
- 1/9/26 - Form 424B5
- ARWR's page on the SEC website